Market Overview

Exact Sciences Shares Up 10.8%; Hearing Analyst At Leerink Out Cautious On Name, Said Word New Guidelines Colon, Rectal Cancer Screenings Should Start At 45 'Only Directionally Positive,' Unlikely To Be A Reality Over The Near Term

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for EXAS

DateFirmActionFromTo
Sep 2018Canaccord GenuityMaintainsBuyBuy
Sep 2018BairdMaintainsOutperformOutperform
Sep 2018Bank of AmericaMaintainsBuyBuy

View More Analyst Ratings for EXAS
View the Latest Analyst Ratings

Posted-In: Analyst Color News Rumors FDA Analyst Ratings Movers Trading Ideas

 

Related Articles (EXAS)

Mid-Day Market Update: Crude Oil Up Over 2%; Chico's FAS Shares Drop On Downbeat Earnings

Allergan Looks To Sell Women's Health, Infectious Disease Businesses